syringaresinol has been researched along with Acute Lung Injury in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, L; Hao, J; Li, C; Li, D; Li, J; Wang, X; Yang, L; Zhang, L; Zhang, Q; Zhang, S; Zhuo, Y | 1 |
| Cui, L; He, S; Hu, D; Wang, X; Yang, L; Zhang, L; Zhang, S; Zhao, J; Zhuo, Y | 1 |
2 other study(ies) available for syringaresinol and Acute Lung Injury
| Article | Year |
|---|---|
Syringaresinol Resisted Sepsis-Induced Acute Lung Injury by Suppressing Pyroptosis Via the Oestrogen Receptor-β Signalling Pathway.
Topics: Acute Lung Injury; Animals; Furans; Lignans; Mice; Mice, Inbred C57BL; Pyroptosis; Receptors, Estrogen; Sepsis | 2022 |
Syringaresinol alleviates IgG immune complex induced acute lung injury via activating PPARγ and suppressing pyroptosis.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Antigen-Antibody Complex; Caspase 1; Immunoglobulin G; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Pneumonia; PPAR gamma; Pyroptosis | 2023 |